"Benzamidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Amidines substituted with a benzene group. Benzamidine and its derivatives are known as peptidase inhibitors.
| Descriptor ID |
D001550
|
| MeSH Number(s) |
D02.078.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamidines".
Below are MeSH descriptors whose meaning is more specific than "Benzamidines".
This graph shows the total number of publications written about "Benzamidines" by people in this website by year, and whether "Benzamidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 5 | 6 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzamidines" by people in Profiles.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. J Virol. 2021 10 13; 95(21):e0097521.
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021 08 31; 12(4):e0097021.
-
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians. Pulm Pharmacol Ther. 2021 10; 70:102055.
-
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment. Int J Mol Sci. 2021 Jun 30; 22(13).
-
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun Biol. 2021 06 03; 4(1):682.
-
A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19. Int J Mol Sci. 2021 Mar 10; 22(6).
-
Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019. J Nippon Med Sch. 2021 Dec 29; 88(6):533-539.
-
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Sci Data. 2021 02 26; 8(1):70.
-
Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations. Appl Biochem Biotechnol. 2021 Jun; 193(6):1909-1923.
-
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. Endocr J. 2021 Apr 28; 68(4):477-484.